Analysts expect Stealth BioTherapeutics Corp (NASDAQ:MITO) to announce ($0.07) earnings per share (EPS) for the current quarter, Zacks Investment Research reports. Zero analysts have provided estimates for Stealth BioTherapeutics’ earnings. The company is scheduled to report its next earnings report on Wednesday, August 21st.
On average, analysts expect that Stealth BioTherapeutics will report full year earnings of ($0.26) per share for the current year. For the next fiscal year, analysts anticipate that the company will report earnings of ($0.22) per share. Zacks’ earnings per share calculations are an average based on a survey of sell-side research firms that cover Stealth BioTherapeutics.
Stealth BioTherapeutics (NASDAQ:MITO) last issued its earnings results on Wednesday, May 15th. The company reported ($0.12) earnings per share for the quarter, topping the consensus estimate of ($0.26) by $0.14.
Shares of MITO stock traded up $0.03 during trading hours on Wednesday, hitting $11.38. The company’s stock had a trading volume of 680 shares, compared to its average volume of 3,259. The stock has a fifty day moving average of $12.38. The firm has a market capitalization of $317.14 million and a PE ratio of -8.07. Stealth BioTherapeutics has a twelve month low of $10.70 and a twelve month high of $20.99.
An institutional investor recently bought a new position in Stealth BioTherapeutics stock. Dean Capital Investments Management LLC purchased a new position in shares of Stealth BioTherapeutics Corp (NASDAQ:MITO) during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm purchased 50,420 shares of the company’s stock, valued at approximately $646,000. Dean Capital Investments Management LLC owned 0.18% of Stealth BioTherapeutics as of its most recent SEC filing. 1.09% of the stock is currently owned by institutional investors.
Stealth BioTherapeutics Company Profile
Stealth BioTherapeutics Corp, a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of therapies for diseases involving mitochondrial dysfunction. Its lead product candidate, Elamipretide, has the potential to treat rare genetic and common age-related mitochondrial diseases.
Recommended Story: Dow Jones Industrial Average (DJIA)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Stealth BioTherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stealth BioTherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.